Integrated MicroRNA and Proteome Analysis Reveal a Regulatory Module in Hepatic Lipid Metabolism Disorders in Mice with Subclinical Hypothyroidism

Overview

Journal Exp Ther Med

Specialty Pathology

Date 2020 Feb 4

PMID 32010250

Citations 8

Authors

Liya Zhang

Kunpeng Wu

Tao Bo

Lingyan Zhou

Ling Gao

Xiaoming Zhou

Wenbin Chen

Affiliations

Soon will be listed here.

Abstract

Subclinical hypothyroidism (SCH) is becoming a global health problem due to its increasing prevalence and potential adverse effects, including cardiovascular diseases and nonalcoholic fatty liver disease (NAFLD). However, the association between SCH and NAFLD remains controversial. MicroRNAs (miRNAs/miRs) have been reported to be implicated in lipid metabolism disorders; however, how miRNAs regulate hepatic lipid metabolism in SCH mice remains unknown. The present study investigated miRNA alterations and proteome profiles in an SCH mouse model, which was generated by methimazole administration in mice for 16 weeks. Next, the profiles of 17 miRNAs that are critical to hepatic lipid metabolism and the proteome were investigated using reverse transcription-quantitative polymerase chain reaction and iTRAQ labeling in the liver specimens of SCH (n=9) and control (n=7) mice. Putative target prediction of miRNAs was also conducted using TargetScan and miRanda. Compared with the control mice, SCH mice had 8 miRNAs and 36 proteins with significantly different expression in the liver tissues. Furthermore, a regulatory module containing 3 miRNAs (miR-34a-5p, miR-24-3p and miR-130a-3p) and 4 proteins (thioredoxin, selenium-binding protein 2, elongation factor 1β and prosaposin) was identified. Overall, integrated analysis of miRNAs and the proteome highlighted a regulatory module between miRNAs and proteins, which, to a certain extent, may contribute to a better understanding of hepatic lipid metabolism disorders in SCH mice.

Citing Articles

Chronic Aroclor 1260 exposure alters the mouse liver proteome, selenoproteins, and metals in steatotic liver disease.

Piell K, Petri B, Xu J, Cai L, Rai S, Li M Environ Toxicol Pharmacol. 2024; 107:104430.

PMID: 38552755 PMC: 11044900. DOI: 10.1016/j.etap.2024.104430.

Association of Differential Metabolites With Small Intestinal Microflora and Maternal Outcomes in Subclinical Hypothyroidism During Pregnancy.

Li J, Xu Y, Cai Y, Zhang M, Sun Z, Ban Y Front Cell Infect Microbiol. 2022; 11:779659.

PMID: 35071037 PMC: 8777023. DOI: 10.3389/fcimb.2021.779659.

Update on dyslipidemia in hypothyroidism: the mechanism of dyslipidemia in hypothyroidism.

Liu H, Peng D Endocr Connect. 2022; 11(2).

PMID: 35015703 PMC: 8859969. DOI: 10.1530/EC-21-0002.

Epigenomics and Lipidomics Integration in Alzheimer Disease: Pathways Involved in Early Stages.

Pena-Bautista C, Alvarez-Sanchez L, Canada-Martinez A, Baquero M, Chafer-Pericas C Biomedicines. 2021; 9(12).

PMID: 34944628 PMC: 8698767. DOI: 10.3390/biomedicines9121812.

Concerted regulation of non-alcoholic fatty liver disease progression by microRNAs in apolipoprotein E-deficient mice.

Lopez-Pastor A, Infante-Menendez J, Gonzalez-Illanes T, Gonzalez-Lopez P, Gonzalez-Rodriguez A, Garcia-Monzon C Dis Model Mech. 2021; 14(12).

PMID: 34850865 PMC: 8713993. DOI: 10.1242/dmm.049173.

References

Quinn T, Gussekloo J, Kearney P, Rodondi N, Stott D . Subclinical thyroid disorders. Lancet. 2012; 380(9839):335-6. DOI: 10.1016/S0140-6736(12)61242-2. View

Iliopoulos D, Drosatos K, Hiyama Y, Goldberg I, Zannis V . MicroRNA-370 controls the expression of microRNA-122 and Cpt1alpha and affects lipid metabolism. J Lipid Res. 2010; 51(6):1513-23. PMC: 3035515. DOI: 10.1194/jlr.M004812. View

Haribabu A, Seshadri Reddy V, Pallavi C, Bitla A, Sachan A, Pullaiah P . Evaluation of protein oxidation and its association with lipid peroxidation and thyrotropin levels in overt and subclinical hypothyroidism. Endocrine. 2012; 44(1):152-7. DOI: 10.1007/s12020-012-9849-y. View

Liu M, Gao M, Li C, Yu C, Yan H, Peng C . Dicer1/miR-29/HMGCR axis contributes to hepatic free cholesterol accumulation in mouse non-alcoholic steatohepatitis. Acta Pharmacol Sin. 2017; 38(5):660-671. PMC: 5457687. DOI: 10.1038/aps.2016.158. View

Castro R, Ferreira D, Afonso M, Borralho P, Machado M, Cortez-Pinto H . miR-34a/SIRT1/p53 is suppressed by ursodeoxycholic acid in the rat liver and activated by disease severity in human non-alcoholic fatty liver disease. J Hepatol. 2012; 58(1):119-25. DOI: 10.1016/j.jhep.2012.08.008. View

Kim Y, Jung H, Seok S, Zhang Y, Ma J, Li T . MicroRNA-210 Promotes Bile Acid-Induced Cholestatic Liver Injury by Targeting Mixed-Lineage Leukemia-4 Methyltransferase in Mice. Hepatology. 2019; 71(6):2118-2134. PMC: 7089843. DOI: 10.1002/hep.30966. View

Surks M, Ortiz E, Daniels G, Sawin C, Col N, Cobin R . Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMA. 2004; 291(2):228-38. DOI: 10.1001/jama.291.2.228. View

Ahn J, Lee H, Chung C, Ha T . High fat diet induced downregulation of microRNA-467b increased lipoprotein lipase in hepatic steatosis. Biochem Biophys Res Commun. 2011; 414(4):664-9. DOI: 10.1016/j.bbrc.2011.09.120. View

Fan J, Li H, Nie X, Yin Z, Zhao Y, Chen C . MiR-30c-5p ameliorates hepatic steatosis in leptin receptor-deficient (db/db) mice via down-regulating FASN. Oncotarget. 2017; 8(8):13450-13463. PMC: 5355111. DOI: 10.18632/oncotarget.14561. View

10.

Seki S, Kitada T, Yamada T, Sakaguchi H, Nakatani K, Wakasa K . In situ detection of lipid peroxidation and oxidative DNA damage in non-alcoholic fatty liver diseases. J Hepatol. 2002; 37(1):56-62. DOI: 10.1016/s0168-8278(02)00073-9. View

11.

Li Y, Wang L, Zhou L, Song Y, Ma S, Yu C . Thyroid stimulating hormone increases hepatic gluconeogenesis via CRTC2. Mol Cell Endocrinol. 2017; 446:70-80. DOI: 10.1016/j.mce.2017.02.015. View

12.

Louten J, Beach M, Palermino K, Weeks M, Holenstein G . MicroRNAs Expressed during Viral Infection: Biomarker Potential and Therapeutic Considerations. Biomark Insights. 2016; 10(Suppl 4):25-52. PMC: 4718089. DOI: 10.4137/BMI.S29512. View

13.

Meng X, Guo J, Fang W, Dou L, Li M, Huang X . Liver MicroRNA-291b-3p Promotes Hepatic Lipogenesis through Negative Regulation of Adenosine 5'-Monophosphate (AMP)-activated Protein Kinase α1. J Biol Chem. 2016; 291(20):10625-34. PMC: 4865911. DOI: 10.1074/jbc.M116.713768. View

14.

Zhang Z, Liu Y, Xiao L, Li S, Jiang J, Zhao Y . Upregulation of miR-125b by estrogen protects against non-alcoholic fatty liver in female mice. J Hepatol. 2015; 63(6):1466-75. DOI: 10.1016/j.jhep.2015.07.037. View

15.

Zhou L, Ding S, Li Y, Wang L, Chen W, Bo T . Endoplasmic Reticulum Stress May Play a Pivotal Role in Lipid Metabolic Disorders in a Novel Mouse Model of Subclinical Hypothyroidism. Sci Rep. 2016; 6:31381. PMC: 4990971. DOI: 10.1038/srep31381. View

16.

Barabasi A, Gulbahce N, Loscalzo J . Network medicine: a network-based approach to human disease. Nat Rev Genet. 2010; 12(1):56-68. PMC: 3140052. DOI: 10.1038/nrg2918. View

17.

Zheng L, Lv G, Sheng J, Yang Y . Effect of miRNA-10b in regulating cellular steatosis level by targeting PPAR-alpha expression, a novel mechanism for the pathogenesis of NAFLD. J Gastroenterol Hepatol. 2009; 25(1):156-63. DOI: 10.1111/j.1440-1746.2009.05949.x. View

18.

Calderon-Gonzalez K, Valero Rustarazo M, Labra-Barrios M, Bazan-Mendez C, Tavera-Tapia A, Herrera-Aguirre M . Determination of the protein expression profiles of breast cancer cell lines by quantitative proteomics using iTRAQ labelling and tandem mass spectrometry. J Proteomics. 2015; 124:50-78. DOI: 10.1016/j.jprot.2015.04.018. View

19.

Miller A, Gilchrist D, Nijjar J, Araldi E, Ramirez C, Lavery C . MiR-155 has a protective role in the development of non-alcoholic hepatosteatosis in mice. PLoS One. 2013; 8(8):e72324. PMC: 3749101. DOI: 10.1371/journal.pone.0072324. View

20.

Wu H, Zhang T, Pan F, Steer C, Li Z, Chen X . MicroRNA-206 prevents hepatosteatosis and hyperglycemia by facilitating insulin signaling and impairing lipogenesis. J Hepatol. 2016; 66(4):816-824. PMC: 5568011. DOI: 10.1016/j.jhep.2016.12.016. View